Drug Trial Radar · NCT06011733
A Study to Evaluate the Efficacy and Safety of Bimekizumab in Chinese Adult Study Participants With Moderate to Severe Plaque Psoriasis
Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
133
Actual
Start
Oct 31, 2023
Primary completion
Feb 5, 2025
Study completion Feb 5, 2025
Sponsor
- Lead sponsor
- UCB Biopharma SRLUCB
- Sponsor type
- Industry
- First posted
- Aug 25, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary purpose of this study is to compare the efficacy of bimekizumab administered subcutaneously (sc) for 16 weeks versus placebo in the treatment of study participants with moderate to severe plaque psoriasis (PSO).
Conditions
- Chronic Plaque Psoriasis
- Moderate to Severe Chronic Plaque Psoriasis
Interventions
PlaceboOther
Study participants will receive placebo subcutaneously at pre-specified time points in the placebo arm as comparator and in the bimekizumab arm to maintain the blinding.
BimekizumabDrug
Study participants will receive bimekizumab (dosage regimen 1 and 2) subcutaneously administered at pre-specified time points during the Initial and Maintenance Treatment Periods.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With Psoriasis Area Severity Index 90 (PASI90) Response at Week 16Time frame: Week 16
- Percentage of Participants With Investigator´s Global Assessment (IGA) 0/1 Response at Week 16Time frame: Week 16
Locations
18 sites in 1 country. Site status is shown where the registry gives one.
Ps0041 20023
Beijing, China
Ps0041 20247
Beijing, China
Ps0041 20306
Beijing, China
Ps0041 20117
Guangzhou, China
Ps0041 20311
Guangzhou, China
Ps0041 20313
Guangzhou, China
Ps0041 20022
Hangzhou, China
Ps0041 20193
Hangzhou, China
Ps0041 20296
Hangzhou, China
Ps0041 20312
Jinan, China
Ps0041 20318
Jinan, China
Ps0041 20310
Ningbo, China
Ps0041 20308
Shanghai, China
Ps0041 20184
Shenzhen, China
Ps0041 20136
Tianjin, China
Ps0041 20120
Wuhan, China
Ps0041 20314
Wuxi, China
Ps0041 20309
Xi'an, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.